NEW YORK, May 6, 2014 /PRNewswire/ --
Today, Analysts Review released its analysts' notes regarding Pacira Pharmaceuticals Inc. (NASDAQ: PCRX), Exact Sciences Corporation (NASDAQ: EXAS), Synageva BioPharma Corp. (NASDAQ: GEVA), Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) and Vanda Pharmaceuticals, Inc. (NASDAQ: VNDA). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/2054-100free.
Pacira Pharmaceuticals Inc. Analyst Notes
On May 1, 2014, Pacira Pharmaceuticals, Inc. (Pacira) reported its Q1 2014 financial results with total revenues of $36.7 million, which grew over three-fold compared to $11.6 million in Q1 2013. Net loss was $11.5 million, or $0.34 per share, compared to $23.1 million, or $0.71 per share, in Q1 2013. Total operating expenses were $45.9 million, compared to $30.2 million in Q1 2013. The Company ended the quarter with cash and cash equivalents and short-term investments of $64.6 million. The full analyst notes on Pacira are available to download free of charge at:
http://www.analystsreview.com/2054-PCRX-06May2014.pdf
Exact Sciences Corporation Analyst Notes
On May 1, 2014, Exact Sciences Corp. (Exact Sciences) reported its Q1 2014 financial results with total revenues of $0.3 million compared to $1 million in Q1 2013. The Company incurred a net loss of $16.1 million or $0.23 per share, compared to a net loss of $10.9 million or $0.17 per share in Q1 2013. Operating expenses totaled $16.5 million compared to $11.9 million in Q1 2013. The Company ended the quarter with cash, cash equivalents and marketable securities of $116.0 million, compared to $133.3 million in 2013. The full analyst notes on Exact Sciences are available to download free of charge at:
http://www.analystsreview.com/2054-EXAS-06May2014.pdf
Synageva BioPharma Corp. Analyst Notes
On April 30, 2014, Synageva BioPharma Corp. (Synageva) reported its Q1 2014 financial results with net loss of $36.4 million, compared to a net loss of $14.5 million in Q1 2013. Revenues for the quarter totaled $1.6 million compared to $5.1 million in Q1 2013. Revenues consisted of Fuzeon royalties from Roche, as well as revenue of $0.1 million from collaborations. Synageva reiterates its previous net loss guidance of between $190 million and $205 million for 2014. The net loss is primarily due to investments supporting the global clinical development program for sebelipase alfa, development of SBC-103, expansion of the global clinical, medical affairs and commercial infrastructure, expansion of manufacturing capabilities, as well as advancement of other preclinical pipeline programs. The full analyst notes on Synageva are available to download free of charge at:
http://www.analystsreview.com/2054-GEVA-06May2014.pdf
Agios Pharmaceuticals, Inc. Analyst Notes
On April 30, 2014, Agios Pharmaceuticals, Inc. (Agios) announced that it will hold a conference call on May 8, 2014, at 8:30 a.m. EDT, to report its Q1 2014 financial results and discuss corporate updates. The live webcast will be made accessible under the Events & Presentations in the Investors and Media section of the Company's website. The full analyst notes on Agios are available to download free of charge at:
http://www.analystsreview.com/2054-AGIO-06May2014.pdf
Vanda Pharmaceuticals, Inc. Analyst Notes
On April 24, 2014, Vanda Pharmaceuticals, Inc. (Vanda Pharmaceuticals) announced that its Q1 2014 scheduled earnings release will be on May 8, 2014, Thursday, before the market opens. In conjunction with its earnings release, the Company will host a conference call at 10:00 a.m. ET on the same day to discuss the results and other corporate activities. The conference call will be broadcast simultaneously and archived on the Company's website. The full analyst notes on Vanda Pharmaceuticals are available to download free of charge at:
http://www.analystsreview.com/2054-VNDA-06May2014.pdf
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.
===============
EDITOR'S NOTES:
===============
1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.
5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
http://www.analystsreview.com/
SOURCE Analysts Review
